Anti-CTLA-4 therapy primarily interferes with the feedback mechanism to improve the proliferation and activation of more T cells, while anti-PD-1 treatment is assumed to attenuate the tumour-induced immunosuppression (29). Here, CTLA4 is linked to neoplasm.